Ixazomib
- Generic Name
- Ixazomib
- Brand Names
- Ninlaro
- Drug Type
- Small Molecule
- Chemical Formula
- C14H19BCl2N2O4
- CAS Number
- 1072833-77-2
- Unique Ingredient Identifier
- 71050168A2
- Background
Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple...
- Indication
Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
- Associated Conditions
- Multiple Myeloma (MM)
- Associated Therapies
- -
Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 46
- Registration Number
- NCT02897830
- Locations
- 🇫🇷
University Hosptial Toulouse, Toulouse, France
A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02831686
- Locations
- 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Nassau, Uniondale, New York, United States
Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement
- Conditions
- Interventions
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT02765854
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Michigan/Rogel Cancer Center, Ann Arbor, Michigan, United States
Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission
- Conditions
- Interventions
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Emory University
- Target Recruit Count
- 12
- Registration Number
- NCT02632396
- Locations
- 🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 3
- Registration Number
- NCT02630030
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Ehab L Atallah
- Registration Number
- NCT02578511
- Locations
- 🇺🇸
Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT02578121
- Locations
- 🇺🇸
University of Arkansas for Medical Science, Little Rock, Arkansas, United States
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
- Conditions
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 11
- Registration Number
- NCT02516423
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Galesburg, Galesburg, Illinois, United States
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
- First Posted Date
- 2015-07-15
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 20
- Registration Number
- NCT02499081
- Locations
- 🇺🇸
University of Arkansas for Medical Science, Little Rock, Arkansas, United States
Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.
- Conditions
- Interventions
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 112
- Registration Number
- NCT02461888
- Locations
- 🇬🇧
Queen Elizabeth Medical Centre, Birmingham, United Kingdom
🇬🇧University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom
🇬🇧Royal Bournemouth General Hospital, Bournemouth, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.